1. Home
  2. MESO vs IART Comparison

MESO vs IART Comparison

Compare MESO & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • IART
  • Stock Information
  • Founded
  • MESO 2004
  • IART 1989
  • Country
  • MESO Australia
  • IART United States
  • Employees
  • MESO N/A
  • IART N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • IART Medical/Dental Instruments
  • Sector
  • MESO Health Care
  • IART Health Care
  • Exchange
  • MESO Nasdaq
  • IART Nasdaq
  • Market Cap
  • MESO 1.3B
  • IART 1.2B
  • IPO Year
  • MESO N/A
  • IART 1995
  • Fundamental
  • Price
  • MESO $14.82
  • IART $15.06
  • Analyst Decision
  • MESO Buy
  • IART Hold
  • Analyst Count
  • MESO 3
  • IART 8
  • Target Price
  • MESO $18.00
  • IART $18.17
  • AVG Volume (30 Days)
  • MESO 230.7K
  • IART 1.3M
  • Earning Date
  • MESO 08-28-2025
  • IART 11-03-2025
  • Dividend Yield
  • MESO N/A
  • IART N/A
  • EPS Growth
  • MESO N/A
  • IART N/A
  • EPS
  • MESO N/A
  • IART N/A
  • Revenue
  • MESO $17,198,000.00
  • IART $1,621,738,000.00
  • Revenue This Year
  • MESO $293.59
  • IART $5.74
  • Revenue Next Year
  • MESO $218.64
  • IART $4.35
  • P/E Ratio
  • MESO N/A
  • IART N/A
  • Revenue Growth
  • MESO 191.39
  • IART 3.53
  • 52 Week Low
  • MESO $6.00
  • IART $11.06
  • 52 Week High
  • MESO $22.00
  • IART $27.13
  • Technical
  • Relative Strength Index (RSI)
  • MESO 50.33
  • IART 55.33
  • Support Level
  • MESO $12.66
  • IART $14.92
  • Resistance Level
  • MESO $15.67
  • IART $15.73
  • Average True Range (ATR)
  • MESO 0.45
  • IART 0.60
  • MACD
  • MESO -0.00
  • IART -0.05
  • Stochastic Oscillator
  • MESO 59.83
  • IART 43.52

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Share on Social Networks: